Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Jannick Prentoe"'
Autor:
Jannick Prentoe, Christoph M. Janitzek, Rodrigo Velázquez-Moctezuma, Andreas Soerensen, Thomas Jørgensen, Stine Clemmensen, Vladislav Soroka, Susan Thrane, Thor Theander, Morten A. Nielsen, Ali Salanti, Jens Bukh, Adam F. Sander
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-10 (2022)
Abstract Development of B-cell-based hepatitis C virus (HCV) vaccines that induce broadly neutralizing antibodies (bNAbs) is hindered by extensive sequence diversity and low immunogenicity of envelope glycoprotein vaccine candidates, most notably sol
Externí odkaz:
https://doaj.org/article/17c5271bc53545d784e5135a4f4c87f6
Autor:
Long V. Pham, Rodrigo Velázquez-Moctezuma, Ulrik Fahnøe, Laura Collignon, Priyanka Bajpai, Christina Sølund, Nina Weis, Kenn Holmbeck, Jannick Prentoe, Jens Bukh
Publikováno v:
Viruses, Vol 14, Iss 11, p 2527 (2022)
Hepatitis C virus (HCV) genotype 4 is highly prevalent in the Middle East and parts of Africa. Subtype 4d has recently spread among high-risk groups in Europe. However, 4d infectious culture systems are not available, hampering studies of drugs, as w
Externí odkaz:
https://doaj.org/article/a1d9cda048864f47943b04977b05abfb
Publikováno v:
PLoS Pathogens, Vol 17, Iss 7, p e1009720 (2021)
Hepatitis C virus (HCV) chronically infects 70 million people worldwide with an estimated annual disease-related mortality of 400,000. A vaccine could prevent spread of this pervasive human pathogen, but has proven difficult to develop, partly due to
Externí odkaz:
https://doaj.org/article/cabd5672ec46492e92b946670c3d469e
Autor:
Jannick Prentoe, Christoph M Janitzek, Rodrigo Velázquez-Moctezuma, Louise Goksøyr, Rebecca W Olsen, Margherita Fanalista, Elias H Augestad, Susan Thrane, Anne F Pihl, Judith M Gottwein, Adam F Sander, Jens Bukh
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0255336 (2021)
Yearly, about 1.5 million people become chronically infected with hepatitis C virus (HCV) and for the 71 million with chronic HCV infection about 400,000 die from related morbidities, including liver cirrhosis and cancer. Effective treatments exist,
Externí odkaz:
https://doaj.org/article/66c39541f9e1496cbb7f3e0e0d294e1a
Autor:
Zhen-Yong Keck, Brian G Pierce, Patrick Lau, Janine Lu, Yong Wang, Alexander Underwood, Rowena A Bull, Jannick Prentoe, Rodrigo Velázquez-Moctezuma, Melanie R Walker, Fabio Luciani, Johnathan D Guest, Catherine Fauvelle, Thomas F Baumert, Jens Bukh, Andrew R Lloyd, Steven K H Foung
Publikováno v:
PLoS Pathogens, Vol 15, Iss 5, p e1007772 (2019)
Cumulative evidence supports a role for neutralizing antibodies contributing to spontaneous viral clearance during acute hepatitis C virus (HCV) infection. Information on the timing and specificity of the B cell response associated with clearance is
Externí odkaz:
https://doaj.org/article/02ca33a0a5d144a7a284f9c9f72f99b4
Autor:
Rodrigo Velázquez-Moctezuma, Elias H. Augestad, Matteo Castelli, Christina Holmboe Olesen, Nicola Clementi, Massimo Clementi, Nicasio Mancini, Jannick Prentoe
Publikováno v:
Vaccines, Vol 9, Iss 3, p 291 (2021)
Hepatitis C virus (HCV) is a major causative agent of acute and chronic hepatitis. It is estimated that 400,000 people die every year from chronic HCV infection, mostly from severe liver-related diseases such as cirrhosis and liver cancer. Although H
Externí odkaz:
https://doaj.org/article/96598d1f2dc14d2885ea21be9b9dc792
Autor:
Garazi Peña Alzua, Anne Finne Pihl, Anna Falden Offersgaard, Rodrigo Velázquez-Moctezuma, Elias Honeroed Augestad, Ulrik Fahnøe, Christian Kjaerulff Mathiesen, Mansun Law, Jannick Prentoe, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
Proceedings, Vol 50, Iss 1, p 5 (2020)
Epitope shielding is suggested as an important mechanism mediating the escape of hepatitis C virus (HCV) from host-neutralizing antibodies (nAb). [...]
Externí odkaz:
https://doaj.org/article/a61c0ec673c84eaa9be32c06e8214dec
Autor:
Jannick Prentoe, Jens Bukh
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Chronic hepatitis C virus (HCV) infection is the cause of about 400,000 annual liver disease-related deaths. The global spread of this important human pathogen can potentially be prevented through the development of a vaccine, but this challenge has
Externí odkaz:
https://doaj.org/article/f70a2362561b49c88194b5dac00cee75
Publikováno v:
PLoS Pathogens, Vol 13, Iss 2, p e1006214 (2017)
Hepatitis C virus (HCV) is a major cause of end-stage liver diseases. With 3-4 million new HCV infections yearly, a vaccine is urgently needed. A better understanding of virus escape from neutralizing antibodies and their corresponding epitopes are i
Externí odkaz:
https://doaj.org/article/bcb2d371b85440ce93dc3cc2ed113c7c
Autor:
Zhen-yong Keck, Jinming Xia, Yong Wang, Wenyan Wang, Thomas Krey, Jannick Prentoe, Thomas Carlsen, Angela Ying-Jian Li, Arvind H Patel, Stanley M Lemon, Jens Bukh, Felix A Rey, Steven K H Foung
Publikováno v:
PLoS Pathogens, Vol 8, Iss 4, p e1002653 (2012)
The majority of broadly neutralizing antibodies to hepatitis C virus (HCV) are against conformational epitopes on the E2 glycoprotein. Many of them recognize overlapping epitopes in a cluster, designated as antigenic domain B, that contains residues
Externí odkaz:
https://doaj.org/article/99cea68e1d0a41cb97e0e5cda0258469